Prostate Cell News Volume 1.23 | Jun 25 2010

    0
    18
    Prostate Cell News 1.23, June 25, 2010.
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  EventsSubscribe  |  Unsubscribe

    TOP STORY

    Large-Scale Genomic Analysis of Prostate Cancer Unveiled
    A unique collaboration among physician-scientists has yielded the most comprehensive genomic analysis of prostate cancer to date. [Press release from the Memorial Sloan-Kettering Cancer Center discussing online prepublication in Cancer Cell]

    Watch Procedure Now 
    Detect 7x More Prostate Epithelial Progenitor Cells
    with ProstaCult

    by STEMCELL Technologies
     
     
    CLICK HERE TO LEARN HOWSTEMCELL Technologies Inc
     



    SCIENCE NEWS

    Gene Study Backs Promise of Breast Cancer Drugs to Treat Hereditary Prostate Cancer
    The way prostate cancer develops in men who have an altered ‘breast cancer gene’ is the same route by which breast cancer develops in women with the same mutation. [Press release from Cancer Research UK discussing online prepublication in PLoS Genetics]

    Chlordecone Exposure and Risk of Prostate Cancer
    Researchers show that exposure to chlordecone (also named Kepone), an organochlorine chemical with well defined estrogenic properties used in the French West Indies until 1993, is associated to a significant increased risk of prostate cancer. [Press release from EurekAlert! discussing online prepublication in the Journal of Clinical Oncology]

    Radium-223 Shows Early Promise In Prostate Cancer Patients With Bone Metastases
    Investigators are reporting favorable results in a phase I pharmacokinetic and biodistribution study in men with bone metastases resulting from castration-resistant prostate cancer who received escalating doses of radium-223. [Medical News Today Press Release]

    Watch Procedure Now 
    Optimized Enzymes and Protocols for
    Prostate Tissue Dissociation

    by STEMCELL Technologies
     
     
    CLICK HERE TO LEARN MORESTEMCELL Technologies Inc
     



    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    Estimation of Effect Size Distribution from Genome-Wide Association Studies and Implications for Future Discoveries
    Researchers report a set of tools to estimate the number of susceptibility loci and the distribution of their effect sizes for a trait on the basis of discoveries from existing genome-wide association studies. [Nat Genet]

    Integrative Genomic Profiling of Human Prostate Cancer
    Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in ~11% of tumors. [Cancer Cell]

    Compensatory Upregulation of Tyrosine Kinase Etk/BMX in Response to Androgen Deprivation Promotes Castration-Resistant Growth of Prostate Cancer Cells
    Here, researchers report that Etk is upregulated in both human and mouse prostates in response to androgen ablation. [Cancer Res]

    Differential Roles of ERK and Akt Pathways in Regulation of EGFR-Mediated Signaling and Motility in Prostate Cancer Cells
    In this study, researchers use the human prostate cancer cell lines, DU145 and PC3, to investigate the effects of both the ERK and Akt pathways on epidermal growth factor (EGF)-mediated EGFR signaling, trafficking and cell motility. [Oncogene]

    The Wnt Inhibitory Factor 1 Restoration in Prostate Cancer Cells was Associated with Reduced Tumor Growth, Decreased Capacity of Cell Migration and Invasion and a Reversal of Epithelial to Mesenchymal Transition
    Researchers investigated the effect and underlying mechanism of a naturally-occurring Wnt inhibitor, WIF1, on the growth and cellular invasiveness of a bone metastatic prostate cancer cell line, PC3. [Mol Cancer]

    Robust Multi-Tissue Gene Panel for Cancer Detection
    Researchers have identified a set of genes whose relative mRNA expression levels in various solid tumors can be used to robustly distinguish cancer from matching normal tissue. [BMC Cancer]

    Chlordecone Exposure and Risk of Prostate Cancer
    Researchers analyzed the relationship between exposure to chlordecone and the risk of prostate cancer. [J Clin Oncol]

    Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-Up Study
    A 10-year prostate cancer-specific mortality of 2.4% among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease. [J Natl Cancer Inst]

    Maximum Tumor Diameter: A Simple Independent Predictor for Biochemical Recurrence after Radical Prostatectomy
    The significance of maximum tumor diameter in biochemical recurrence (BCR) prediction was evaluated using radical prostatectomy specimens of 364 patients with a BCR of 18% (n=66) during a mean follow-up of 37.4 months. [Prostate Cancer Prostatic Dis]



    INDUSTRY NEWS

    Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review
    Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing treatment regimen. [Sanofi-aventis Press Release]

    CIRM Allocates $25 Million to Overcome Immune Rejection of Stem Cell Transplantation Therapies
    The Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by proposition 71, approved $25 million to fund 19 projects intended to overcome immune rejection of transplanted stem cells. [California Institute for Regenerative Medicine Press Release]



    POLICY NEWS

    Hospital Clínic de Barcelona Obtained the First Accreditation for Cell Therapy Research
    The certification, awarded for the first time in Catalonia, allows the Hospital Clínic de Barcelona to produce drugs in gene therapy, cell therapy and tissue engineering. [Spanish Medicines Agency, Spain]

    New Videos Reveal How NIH Identifies the Most Promising Research Applications
    The National Institutes of Health’s Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States]

    NIH and Wellcome Trust Announce Partnership to Support Genomic, Population-Based Studies in Africa
    The National Institutes of Health (NIH) and the Wellcome Trust announced a partnership with African researchers to conduct genetic and environmental studies in Africa of common, non-communicable disorders, such as heart disease and cancer, as well as communicable diseases, such as malaria. [National Institutes of Health, United States]

    Publication of New Enforcement Strategy
    A new enforcement strategy has been published by the Inspection, Enforcement and Standards Division. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

    FDA/CDRH Public Meeting: Oversight of Laboratory Developed Tests (LDTs), Date July 19-20, 2010 [Food and Drug Administration, United States]

    Drugs Designated as Orphan Drugs [Therapeutic Goods Administration, Australia]

    Therapeutic Goods Committee (TGC) (Updated) [Therapeutic Goods Administration, Australia]



    EVENTS

    21st Meeting of the European Association for Cancer Research (EACR) 
    June 26-29, 2010
    Oslo, Norway

    Translational Cancer Medicine 2010 – USA
    July 11-14, 2010
    San Francisco, United States

    United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
    July 12-14, 2010
    Nottingham, United Kingdom

    2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
    August 2-4, 2010
    Singapore City, Singapore

    CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
    August 17-19, 2010
    Cambridge, United States

    2010 World Cancer Congress
    August 18-21, 2010
    Shenzhen, China

    Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
    August 23-27, 2010
    Toronto, Canada

    Select Biosciences 3rd Annual Stem Cells Europe Conference
    August 24-25, 2010
    Edinburgh, Scotland

    Select Biosciences 2nd Annual World Biobanking Summit
    August 24-25, 2010
    Edinburgh, Scotland

    Select Biosciences Inaugural Cellular Therapy Summit
    August 24-25, 2010
    Edinburgh, Scotland

    28th World Congress of Endourology and SWL
    September 1-4, 2010
    Chicago, United States

    International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
    September 11-14, 2010
    Belgirate, Italy

    35th European Society for Medical Oncology (ESMO) Congress
    October 8–12, 2010
    Milan, Italy

    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



    JOB OPPORTUNITIES


    Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

    Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

    Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

    Recruit Top Talent

    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
    Visit here to post your career opportunities.

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.


    Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us